Janus

Edison issues flash on Henderson EuroTrust (HNE): Proposed merger with Henderson European Focus Trust

Retrieved on: 
Wednesday, April 10, 2024
Janus, HNE, HEFT, Philosophy, Security (finance)

On 14 March, the boards of Henderson European Focus Trust (HEFT) and Henderson EuroTrust (HNE) announced the proposed merger of the two companies to form Henderson European Trust.

Key Points: 
  • On 14 March, the boards of Henderson European Focus Trust (HEFT) and Henderson EuroTrust (HNE) announced the proposed merger of the two companies to form Henderson European Trust.
  • The resulting enlarged fund will be managed by Janus Henderson Investors’ (JHI’s) European equities team.
  • There will be two co-managers, Tom O’Hara (currently co-lead manager of HEFT) and Jamie Ross (currently lead manager of HNE).
  • There will be two dividend payments a year; payments are expected to normalise at the end of FY25 (30 September).

Intech Continues Momentum with Feature in FundFire, Following P&I Highlight

Retrieved on: 
Tuesday, April 9, 2024
Janus, Optimism, PALM, Crain Communications

Following a detailed feature in Pensions & Investments that highlighted the firm's turnaround post-management buyout, FundFire has now released an insightful article, "Intech 2.0?

Key Points: 
  • Following a detailed feature in Pensions & Investments that highlighted the firm's turnaround post-management buyout, FundFire has now released an insightful article, "Intech 2.0?
  • How the Firm Plans to Recover From a 75% Asset Plunge," penned by financial reporter Bridget Hickey.
  • This latest feature in FundFire offers an in-depth look at Intech's strategic efforts and innovations since its separation from Janus Henderson in 2022.
  • "This feature, along with our recent highlight in Pensions & Investments, reflects our dedication to innovation and our commitment to delivering superior results for our clients."

Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart

Retrieved on: 
Tuesday, April 2, 2024
Janus, Week, CD154, Rheumatoid arthritis, Jaki, Patient, Cohort, KNSA, Joint, Clinical trial, C-reactive protein, CD40, Least squares, Pharmacokinetics, Safety, FDA, Rheumatoid factor, Pharmaceutical industry

HAMILTON, Bermuda, April 02, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a commercial-stage biopharmaceutical company with a pipeline of immune-modulating assets designed to target a spectrum of cardiovascular and autoimmune diseases, today announced plans to initiate a Phase 2b trial with abiprubart in Sjogren’s Disease. Additionally, the company announced data from Cohort 4 of the Phase 2 clinical trial of abiprubart in rheumatoid arthritis. Abiprubart is an investigational humanized anti-CD40 monoclonal antibody designed to inhibit CD40-CD154 (CD40 ligand) interaction.

Key Points: 
  • HAMILTON, Bermuda, April 02, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a commercial-stage biopharmaceutical company with a pipeline of immune-modulating assets designed to target a spectrum of cardiovascular and autoimmune diseases, today announced plans to initiate a Phase 2b trial with abiprubart in Sjogren’s Disease.
  • Additionally, the company announced data from Cohort 4 of the Phase 2 clinical trial of abiprubart in rheumatoid arthritis.
  • Abiprubart is an investigational humanized anti-CD40 monoclonal antibody designed to inhibit CD40-CD154 (CD40 ligand) interaction.
  • “We believe abiprubart has the potential to provide meaningful benefit to patients suffering from Sjogren’s Disease, a debilitating disorder with no current FDA-approved therapies.

Blüm Responds to Allegations of Child Molestation By Bernard Steimann, “People’s California” Managing Member; Denounces Sexual Abuse of Children

Retrieved on: 
Thursday, March 28, 2024
Janus, Minor, Culture, Child protective services, Child, General counsel, Domestic violence, Seriousness, Record, Nature, National Domestic Violence Hotline, OTCQB, PFC, Violence

The statement is released in response to recently filed court documents that contain explicit detail of Bernard Steimann’s alleged sexual molestation of a minor.

Key Points: 
  • The statement is released in response to recently filed court documents that contain explicit detail of Bernard Steimann’s alleged sexual molestation of a minor.
  • The records indicate that a Request For Child Abduction Prevention Orders was filed as recently as March 19, 2024.
  • Blüm acknowledges that the allegations are not a determination of Mr. Steimann’s guilt or innocence, and trusts that they will be investigated by the appropriate authorities.
  • Nevertheless, the Company must take allegations of the nature described in the court documents with the utmost seriousness and concern.

Nkarta Announces Pricing of $240 Million Underwritten Offering

Retrieved on: 
Monday, March 25, 2024
Janus, SVB Securities, Montgomery Street, Mizuho Securities, 3rd Floor, Telephone, SAN, Research, Sale, Attention, Security (finance), Lexington Avenue, Prospectus, Suite, Annual report, OrbiMed, Equity capital markets, NK, State Street

Gross proceeds to Nkarta from this offering are approximately $240.1 million, before deducting underwriting discounts and commissions and offering expenses.

Key Points: 
  • Gross proceeds to Nkarta from this offering are approximately $240.1 million, before deducting underwriting discounts and commissions and offering expenses.
  • The offering is expected to close on or about March 27, 2024, subject to customary closing conditions.
  • All securities in the offering are to be issued and sold by Nkarta.
  • The offering was made only by means of a prospectus supplement and accompanying prospectus describing the terms of the offering.

Current and Former Public Company Directors Send Letter to Disney Board In Support of Nelson Peltz and Trian

Retrieved on: 
Thursday, March 21, 2024
Janus, University of Georgia, Letter, Growth, The Walt Disney Company, The Home Depot, Henry J. Heinz, Sysco, Synovial joint, Legg Mason, Art, University, Corus Entertainment, Thought, Terry College of Business, Procter & Gamble, Lead, Management

NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- Current and former public company directors who have worked with Nelson Peltz and Trian today sent a letter to The Walt Disney Company (NYSE: DIS) Board of Directors detailing their positive experiences working with Trian.

Key Points: 
  • NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- Current and former public company directors who have worked with Nelson Peltz and Trian today sent a letter to The Walt Disney Company (NYSE: DIS) Board of Directors detailing their positive experiences working with Trian.
  • The letter details Trian and Nelson Peltz’s demonstrated ability to work collaboratively and constructively with board members and management teams to drive long-term shareholder value, and its signatories include former directors at H.J.
  • The companies for which we served as board members alongside Nelson were improved because of his presence on the board.
  • Others of us asked Nelson to join our boards, and still others of us joined a board after Nelson was already on the board.

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY2023 Financial Results

Retrieved on: 
Thursday, March 21, 2024
Janus, Research, MMN, Myasthenia gravis, Dianthus, GMG, CIDP, Half-life, Form, Patient, Complement component 1s, Magenta, Acetylcholine, American Academy, CMC, G&A, YTE, Drug, AAN, Investment, Therapy, PIPE, Magic, Multifocal motor neuropathy, Annual general meeting, Pharmaceutical industry

NEW YORK and WALTHAM, Mass., March 21, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today reported financial results for the fourth quarter and full year ending December 31, 2023, and provided an update on recent business achievements.

Key Points: 
  • DNTH103 has the potential to be a best-in-class pipeline-in-a-product across a range of autoimmune disorders with high unmet need.
  • Initial top-line results from this trial are anticipated to be available in the second half of 2025.
  • Dianthus successfully completed a private investment in public equity (“PIPE”) financing in January 2024 that resulted in gross proceeds of approximately $230 million.
  • Additional Information – For additional information on the Company’s financial results for the year ended December 31, 2023, please refer to the Form 10-K filed with the SEC.

Janus Henderson to Report First Quarter 2024 Results

Retrieved on: 
Friday, April 5, 2024
Asset Management, Professional Services, Finance, Janus

To eliminate wait times, conference call participants may pre-register at https://www.netroadshow.com/events/login?show=8419fbb6&confId=62696 .

Key Points: 
  • To eliminate wait times, conference call participants may pre-register at https://www.netroadshow.com/events/login?show=8419fbb6&confId=62696 .
  • After registering, a confirmation with access details will be sent via email.
  • Access to the live webcast and accompanying slides will be available via the investor relations section of Janus Henderson’s website ( ir.janushenderson.com ); a webcast replay will be available following the call.

Obsidian Therapeutics Announces Oversubscribed $160.5 Million Series C Financing to Drive OBX-115 Clinical Development

Retrieved on: 
Wednesday, April 3, 2024
Biotechnology, Health, Genetics, Clinical Trials, Oncology, Janus, Growth, Novo Holdings A/S, NSCLC, TIL, Patient, Wellington Management Company, Paradigm, Foresite Capital, Bristol Myers Squibb, Lung cancer, Doctor of Philosophy, Therapy, Melanoma, Investment, Atlas Venture, Pharmaceutical industry

Obsidian Therapeutics, Inc. , a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced it has closed a significantly oversubscribed $160.5 million Series C financing with a top-tier syndicate of life science investors led by new investor, Wellington Management.

Key Points: 
  • Obsidian Therapeutics, Inc. , a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced it has closed a significantly oversubscribed $160.5 million Series C financing with a top-tier syndicate of life science investors led by new investor, Wellington Management.
  • Proceeds from the financing will advance Obsidian’s lead engineered tumor-infiltrating lymphocyte (TIL) program, OBX-115, in its ongoing trials for patients with melanoma and non-small cell lung cancer (NSCLC).
  • The Company is focused on enrolling patients and reaching key clinical and regulatory milestones, as well as manufacturing scale-up ahead of pivotal trial readiness.
  • “This financing provides funding through key clinical readouts in melanoma and is the catalyst to continue expanding OBX-115 into NSCLC, where there is significant potential and high unmet need.”

Janus International Group Announces All-New Internal, Hardwired Smart Lock

Retrieved on: 
Tuesday, April 2, 2024
Commercial Building & Real Estate, Technology, Manufacturing, Construction & Property, Building Systems, Security, Other Manufacturing, Apps, Applications, Software, Mobile, Wireless, Hardware, Janus, Cloud, Automation, LED, JBI, International Marxist Group, Baggage

In addition to the all-new, hardwired smart locking solution, Janus’s Nokē Smart Entry platform also offers a high-tech, battery-powered external smart lock, known as Nokē ONE™.

Key Points: 
  • In addition to the all-new, hardwired smart locking solution, Janus’s Nokē Smart Entry platform also offers a high-tech, battery-powered external smart lock, known as Nokē ONE™.
  • These two smart locking technologies, paired with a full suite of smart entry point products and mobile technology, offer a solution for all self-storage smart access applications.
  • Nokē Ion is a sleek, yet powerful hardwired smart lock that fits on the inside track of the door and boasts an innovative, yet simplified design.
  • The Nokē Smart Entry System by Janus combines its best-in-class self-storage offerings with new and innovative technologies to redefine the total self-storage experience.